Skip to main content

3 Result(s)

within Protocol Remove this filter Gang** Han Remove this filter

and

  1. No Access

    Protocol

    Nano-optogenetic CAR-T Cell Immunotherapy

    Chimeric antigen receptor (CAR)-T cell immunotherapy emerges as an effective cancer treatment. However, significant safety concerns remain, such as cytokine release syndrome (CRS) and “on-target, off-tumor” cy...

    Nhung Thi Nguyen, Siyao Liu, Gang Han, Yubin Zhou, Kai Huang in Cancer Immunotherapy (2024)

  2. No Access

    Protocol

    Use of Glycine to Augment Exon Skip** and Cell Therapies for Duchenne Muscular Dystrophy

    Antisense oligonucleotide (AO)-based exon-skip** and cell therapies are the main therapeutic approaches for Duchenne muscular dystrophy (DMD). Insufficient systemic delivery leading to low therapeutic effica...

    Gang Han, Caorui Lin, HaiFang Yin in Muscular Dystrophy Therapeutics (2023)

  3. No Access

    Protocol

    Use of Glucose–Fructose to Enhance the Exon Skip** Efficacy

    Exon-skip** antisense oligonucleotides (AOs) are promising treatments for muscle-related genetic ailments including Duchenne muscular dystrophy (DMD), but clinical translation is unfortunately hampered by in...

    Gang Han, **anjun Gao, Haifang Yin in Exon Skip** and Inclusion Therapies (2018)